Pfizer Inc. (PFE) Shares Bought by Voya Investment Management LLC
Voya Investment Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,267,149 shares of the biopharmaceutical company’s stock after purchasing an additional 237,581 shares during the period. Pfizer comprises about 0.7% of Voya Investment Management LLC’s holdings, making the stock its 21st largest position. Voya Investment Management LLC owned 0.16% of Pfizer worth $311,284,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Shine Investment Advisory Services Inc. purchased a new position in shares of Pfizer during the second quarter worth about $102,000. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer during the second quarter worth about $103,000. D. Scott Neal Inc. grew its holdings in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC purchased a new position in shares of Pfizer during the second quarter worth about $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer during the first quarter worth about $121,000. Institutional investors and hedge funds own 69.89% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded up $0.24 during trading hours on Friday, hitting $35.74. The stock had a trading volume of 14,580,055 shares, compared to its average volume of 14,347,659. The stock has a market cap of $211,605.09, a price-to-earnings ratio of 14.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.78.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 EPS. sell-side analysts expect that Pfizer Inc. will post 2.59 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.58%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 79.01%.
In other news, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold a total of 60,280 shares of company stock worth $2,118,988 in the last three months. Corporate insiders own 0.06% of the company’s stock.
A number of research firms recently issued reports on PFE. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, October 3rd. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a report on Wednesday, September 13th. Cowen set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Finally, Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Buy” and an average target price of $38.77.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.